Assertion: polypeptide's domain | /r/HasAspect | a leu16vhy/vkz-il2 molecule
Facets:
Source sentences:
text: Depending on the application and the desired frequency of administration, it may be preferable to use a Leu16VhY/VkZ-IL2 molecule with the N-linked glycosylation site in the CH2 domain, which has ADCC activity but a relatively shorter serum half-life, or a Leu16VhY/VkZ-IL2 molecule lacking the N-linked glycosylation site in the CH2 domain, which has no ADCC activity but a relatively longer serum half-life.
text: Depending on the application and the desired frequency of administration, it may be preferable to use a Leu16VhY/VkZ-IL2 molecule with the N-linked glycosylation site in the CH2 domain, which has ADCC activity but a relatively shorter serum half-life, or a Leu16VhY/VkZ-IL2 molecule lacking the N-linked glycosylation site in the CH2 domain, which has no ADCC activity but a relatively longer serum half-life.